667463-68-5

Basic information

• Product Name: 6-BroMo-5-nitroindoline-2,3-dione
• Synonyms: 6-BroMo-5-nitroindoline-2,3-dione;6-Bromo-5-nitroisatin;6-Bromo-5-nitro-1H-indole-2,3-dione
• CAS NO: 667463-68-5
• Molecular Formula: C8H3BrN2O4
• Molecular Weight: 271.02442
• Mol File: 667463-68-5.mol

Chemical Properties

• Melting Point: 251-253 °C
• Appearance: /
• Density: 1.998±0.06 g/cm3(Predicted)
• PKA: 7.04±0.20(Predicted)
• CAS DataBase Reference: 6-BroMo-5-nitroindoline-2,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-5-nitroindoline-2,3-dione(667463-68-5)
• EPA Substance Registry System: 6-BroMo-5-nitroindoline-2,3-dione(667463-68-5)

Safety Data

• Hazardous Substances Data: 667463-68-5(Hazardous Substances Data)

Upstream product

• 65971-74-6 N-(3-bromophenyl)-2-(hydroxyimino)ethanamide 
• 591-19-5 m-Bromoaniline 
• 6326-79-0 6-bromoisatin 

Relevant articles and documents

BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS

The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

In vitro cytotoxicity evaluation of some substituted isatin derivatives

A range of substituted 1H-indole-2,3-diones (isatins) were synthesized using standard procedures and their cytotoxicity evaluated against the human monocyte-like histiocytic lymphoma (U937) cell line in vitro. SAR studies identified C5, C6

INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE

Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.

Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3β, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.